Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
David Counter
Observed names:
Counter, David,
D Counter
Observed institutions:
University of Dundee,
Aberdeen Royal Infirmary,
James Cook University Hospital,
NHS Grampian,
Medical Research Council
ORCID:
0000-0002-2052-9134
Observed ORCID:
0000-0002-2052-9134
OpenAlex ID:
A5013413298
Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
2021
·
Eugenia Abaleke
, Mustafa Abbas
, et al.
·
The Lancet
·
533
PDF
Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial
2021
·
Obbina Abani
, Ali Abbas
, et al.
·
The Lancet
·
493
Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
2022
·
Obbina Abani
, Ali Abbas
, et al.
·
The Lancet
·
369
Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis
2022
·
Obbina Abani
, Ali Abbas
, et al.
·
The Lancet
·
324
Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
2021
·
Obbina Abani
, Ali Abbas
, et al.
·
The Lancet
·
290
Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial
2023
·
Obbina Abani
, Ali Abbas
, et al.
·
The Lancet
·
129
Lorundrostat in Participants With Uncontrolled Hypertension and Treatment-Resistant Hypertension
2025
·
Manish Saxena
, Luke Laffin
, et al.
·
JAMA
·
108
PDF
Hospital readmissions, mortality and potentially inappropriate prescribing: a retrospective study of older adults discharged from hospital
2018
·
David Counter
, James W. T. Millar
, et al.
·
British Journal of Clinical Pharmacology
·
101
Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
2023
·
O Abani
, A Abbas
, et al.
·
The Lancet Diabetes & Endocrinology
·
41
PDF
Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trial
2024
·
Saul N Faust
, Richard Haynes
, et al.
·
The Lancet Child & Adolescent Health
·
39
PDF
Multicompartment compliance aids in the community: the prevalence of potentially inappropriate medications
2016
·
David Counter
, Derek Stewart
, et al.
·
British Journal of Clinical Pharmacology
·
17
PDF
Molnupiravir or nirmatrelvir–ritonavir plus usual care versus usual care alone in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
2025
·
O Abani
, A Abbas
, et al.
·
The Lancet Infectious Diseases
·
12
PDF
Sotrovimab versus usual care in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
2025
·
O Abani
, A Abbas
, et al.
·
The Lancet Infectious Diseases
PDF
Show more works
View as search
Works count:
14
Citation count:
2,453
H-index:
12
I10-index:
12
Year
Topic
Type
